Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Clinical Trials

20 clinical trials for Diffuse Large B-Cell Lymphoma, Not Otherwise Specified across international registries, including 7 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma — RECRUITING · PHASE2
• Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma — RECRUITING · PHASE1
• Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma — RECRUITING · PHASE2
• Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma — RECRUITING · PHASE1
• ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL — RECRUITING · NA
• A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies — RECRUITING · PHASE1
• Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy — RECRUITING · PHASE2
• AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") — NOT_YET_RECRUITING · PHASE1
• Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma — ACTIVE_NOT_RECRUITING · NA
• Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas — ACTIVE_NOT_RECRUITING · PHASE2
• Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas — ACTIVE_NOT_RECRUITING · PHASE2
• P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma — TERMINATED · PHASE2
• Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma — COMPLETED · PHASE1
• Expanded Access Program for Epcoritamab — OTHER
• Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients — WITHDRAWN · NA
• Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma — OTHER · PHASE4
• JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma — TERMINATED · PHASE1

Refine this search